KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Receivables (2016 - 2025)

Fulgent Genetics' Receivables history spans 10 years, with the latest figure at $85.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 21.34% year-over-year to $85.9 million; the TTM value through Dec 2025 reached $85.9 million, up 21.34%, while the annual FY2025 figure was $85.9 million, 21.34% up from the prior year.
  • Receivables for Q4 2025 was $85.9 million at Fulgent Genetics, up from $72.6 million in the prior quarter.
  • Across five years, Receivables topped out at $216.5 million in Q1 2021 and bottomed at $35.7 million in Q2 2023.
  • The 5-year median for Receivables is $73.3 million (2025), against an average of $91.7 million.
  • The largest annual shift saw Receivables soared 3281.38% in 2021 before it tumbled 73.24% in 2023.
  • A 5-year view of Receivables shows it stood at $140.3 million in 2021, then tumbled by 48.27% to $72.6 million in 2022, then fell by 27.74% to $52.5 million in 2023, then soared by 34.96% to $70.8 million in 2024, then grew by 21.34% to $85.9 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Receivables are $85.9 million (Q4 2025), $72.6 million (Q3 2025), and $79.2 million (Q2 2025).